The FDA’s approval of Rocklatan and news updates from the American Glaucoma Society meeting were among the most-read glaucoma-related articles on Healio.com/OSN in recent weeks.
Here are the top five recent glaucoma stories:
FDA approves Rocklatan for open-angle glaucoma, ocular hypertension
A fixed-dose combination of netarsudil and latanoprost, Rocklatan — previously known as Roclatan — is designed to target the trabecular meshwork, which is considered the main cause of elevated IOP. Read more.
Kahook Dual Blade reduces IOP with and without phaco
The Kahook Dual Blade procedure, with or without phacoemulsification, reduced IOP at 18 months, even more so in eyes with pseudoexfoliation, according to a poster presented at the American Glaucoma Society meeting. Read more.
Dysphotopsias after LPI tend to resolve
Most patients who report new dysphotopsias after laser peripheral iridotomy for primary angle-closure glaucoma can be reassured that these manifestations are likely to resolve, Nazlee Zebardast, MD, told colleagues at the American Glaucoma Society meeting. Read more.
iStent reduced IOP and medications through 5 years
A cohort of patients with open-angle glaucoma or ocular hypertension implanted with an iStent after cataract surgery experienced reduced, safe and durable IOP and reduced medications through 5 years after the procedure. Read more.
Prophylactic laser peripheral iridotomy may be overused
At the American Glaucoma Society annual meeting, David S. Friedman, MD, MPH, PhD, delivered 72-month findings of the Zhongshan Angle Closure Prevention (ZAP) study, which looked at Chinese patients with PACS bilaterally who underwent laser peripheral iridotomy in one eye with the contralateral eye remaining untreated. Read more.